Positron Corp. is a cardiac health solutions company engaged in radiopharmeceutical development and the advancement of current internal imaging technologies. The radiopharmeceutical sector of American nuclear cardiology is a $1.2 billion dollar industry, and Positron Corp. has now teamed up with Disease Management, LLC, to increase its market share.
The two companies have agreed to co-develop a heart disease prevention and reversal software suite; the key component of a total coronary disease management solution. The proposed system will include a preliminary risk-assessment calculator, a coronary disease reversal program, and corresponding lifestyle modification regimen. These features will be backed by a cost-controlled patient outcomes tracker.
Joseph Oliverio, president of Positron Corp.commented on the project: “The development of our heart disease management solution will help us reach beyond our current molecular imaging targeted business to offer a product to payers, self insured corporations, multi-specialty groups, cardiology groups, hospitals and finally direct to the consumer.”
Mr. Oliverio noted the importance of this step in the growth of his company, and the services it provides. He went on to add: “The product introduction will address a first-to-market opportunity in the Coronary Disease Reversal and Prevention sector which strengthens Positron’s core products that are focused on providing accurate, cost effective imaging and disease management solutions. One of our many goals is to offer even the smallest community hospitals the same level of quality of our most experienced users.”
Let us hear your thoughts below: